Press Releases

 
Press Releases
Date Title and Summary View
Jan 22, 2015 SALT LAKE CITY, Jan. 22, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Johnathan M. Lancaster, M.D., Ph.D. has joined the Company as the vice president of Medical Affairs for Oncology, Myriad Genetic Laboratories, effective Feb. 9, 2015. In this new role, Dr. Lancaster will provide medical and scientific leadersh...
Jan 21, 2015 SALT LAKE CITY, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal second quarter 2015 and provide a business update following the close of market on Tuesday, February 3, 2015. The Company also will host a conference call at 4:30 p.m. ET on February 3, 2015 t...
Jan 20, 2015 SALT LAKE CITY, Jan. 20, 2015 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis (TB) epidemic. This research project is funded by the Bill & Melinda Gates Foundation thr...
Jan 8, 2015 SALT LAKE CITY and ZURICH, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the Company has obtained CE Marking in Europe for its Tumor BRACAnalysis CDx test, which identifies tumors that have mutations in the BRCA1 or BRCA2 genes. Tumor BRACAnalysis CDx is the first and only tumor-based companion diagnostic that...
Jan 5, 2015 SALT LAKE CITY, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad Genetics, is scheduled to present at the J.P. Morgan 33rd Annual Healthcare Conference at 9:30 a.m. Pacific on January 12, 2015, at the Westin St. Francis in San Francisco, California. The prese...
Dec 22, 2014 SALT LAKE CITY, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the appointment of Bernard F. Tobin as president of Crescendo Bioscience, effective January 5, 2015. Mr. Tobin will report to Peter D. Meldrum, president and CEO, Myriad Genetics, Inc., and will succeed William Hagstrom, who has chosen to pursue ne...
Dec 19, 2014 SALT LAKE CITY, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for BRACAnalysis CDx to be used as the only companion diagnostic in conjunction with AstraZeneca's drug Lynparza™ (olaparib). Lynparza is the first poly ADP-ribose...
Dec 9, 2014 Myriad myRisk™ Hereditary Cancer Test Finds 105 Percent More MutationsMyriad myChoice™ HRD Predicted Platinum Response in Early TNBCBRACAnalysis®Predicted Platinum Response in Metastatic TNBC SALT LAKE CITY, Dec. 9, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results from a new study that demons...
Dec 3, 2014 SALT LAKE CITY, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the presentation of eight new studies evaluating the use of its molecular and companion diagnostics in patients with breast cancer at the 2014 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, Dec. 9-13. Several studies will feature...
Dec 2, 2014 SALT LAKE CITY, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology (SUO) Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could sa...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase